CULLINAN ONCOLOGY LLC

NASDAQ: CGEM (Cullinan Therapeutics, Inc.)

Kemas kini terakhir: 4 hari lalu, 5:41AM

10.50

0.30 (2.94%)

Penutupan Terdahulu 10.20
Buka 10.18
Jumlah Dagangan 936,036
Purata Dagangan (3B) 1,147,450
Modal Pasaran 620,300,736
Harga / Buku (P/B) 1.49
Julat 52 Minggu
5.68 (-45%) — 13.60 (29%)
Tarikh Pendapatan 6 Nov 2025
EPS Cair (TTM) -2.77
Jumlah Hutang/Ekuiti (D/E MRQ) 0.33%
Nisbah Semasa (MRQ) 11.62
Aliran Tunai Operasi (OCF TTM) -150.21 M
Aliran Tunai Bebas Leveraj (LFCF TTM) -87.13 M
Pulangan Atas Aset (ROA TTM) -25.38%
Pulangan Atas Ekuiti (ROE TTM) -36.57%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Biotechnology (US) Menaik Bercampur
Biotechnology (Global) Menaik Bercampur
Stok Cullinan Therapeutics, Inc. Menaik Menaik

AISkor Stockmoo

0.2
Konsensus Penganalisis 5.0
Aktiviti Orang Dalam -1.5
Volatiliti Harga -4.5
Purata Bergerak Teknikal 0.0
Osilator Teknikal 2.0
Purata 0.20

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
CGEM 620 M - - 1.49
MESO 2 B - - 3.70
TSHA 1 B - - 5.08
SANA 1 B - - 6.10
NTLA 1 B - - 1.32
ORIC 1 B - - 2.83

Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.

Sektor Healthcare
Industri Biotechnology
Gaya Pelaburan Small Value
% Dimiliki oleh Orang Dalam 4.55%
% Dimiliki oleh Institusi 116.27%
Julat 52 Minggu
5.68 (-45%) — 13.60 (29%)
Julat Harga Sasaran
26.00 (147%) — 38.00 (261%)
Tinggi 38.00 (BTIG, 261.91%) Beli
Median 32.00 (204.76%)
Rendah 26.00 (HC Wainwright & Co., 147.62%) Beli
Purata 32.00 (204.76%)
Jumlah 2 Beli
Harga Purata @ Panggilan 10.83
Syarikat Tarikh Harga Sasaran Panggilan Harga @ Panggilan
BTIG 24 Nov 2025 38.00 (261.90%) Beli 12.93
10 Sep 2025 32.00 (204.76%) Beli 6.47
HC Wainwright & Co. 20 Nov 2025 26.00 (147.62%) Beli 8.72
12 Sep 2025 24.00 (128.57%) Beli 6.53
Nama Purata Belian ($) Purata Jualan ($) Jumlah Net Jumlah Nilai Bersih ($)
MICHAELSON JENNIFER - 12.93 -4,000 -51,720
Jumlah Keseluruhan Kuantiti Bersih -4,000
Jumlah Keseluruhan Nilai Bersih ($) -51,720
Purata Pembelian Keseluruhan ($) -
Purata Jualan Keseluruhan ($) 12.93
Nama Pemegang Tarikh Jenis Kuantiti Harga Nilai ($)
MICHAELSON JENNIFER Pegawai 24 Nov 2025 Jual automatik (-) 4,000 12.93 51,720
Tarikh Jenis Butiran
01 Dec 2025 Pengumuman Cullinan Therapeutics Receives FDA Fast Track Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia
20 Nov 2025 Pengumuman Taiho Oncology, Taiho Pharmaceutical and Cullinan Therapeutics Initiate Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Zipalertinib for Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EG...
10 Nov 2025 Pengumuman Cullinan Therapeutics to Participate in Upcoming Investor Conferences and Host Analyst and Investor Event at 2025 ASH Annual Meeting
06 Nov 2025 Pengumuman Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results
03 Nov 2025 Pengumuman Cullinan Therapeutics to Showcase New Data Demonstrating Compelling Clinical Activity for CLN-049, a Novel FLT3xCD3 T Cell Engager, in AML Patients in an Oral Presentation at the 67th ASH Annual Meeting
25 Oct 2025 Pengumuman Cullinan Therapeutics Shares Additional Preclinical B Cell Depletion Data for CLN-978, Supporting Clinical Development Across Multiple Autoimmune Diseases, at ACR Convergence 2025
12 Oct 2025 Pengumuman Taiho Oncology and Cullinan Therapeutics Present Data on Zipalertinib in Patients with NSCLC with EGFR mutations and Active Brain Metastases at the ESMO Congress 2025
12 Sep 2025 Pengumuman Cullinan Therapeutics to Participate in Fireside Chat at the Stifel 2025 Virtual Immunology and Inflammation Forum
09 Sep 2025 Pengumuman Taiho Oncology and Cullinan Therapeutics Present Data on Zipalertinib at the IASLC 2025 World Conference on Lung Cancer

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2025 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda